Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-05-09
2006-05-09
Nguyen, Dave Trong (Department: 1633)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C530S300000, C530S388400, C424S009340, C424S190100, C514S002600
Reexamination Certificate
active
07041295
ABSTRACT:
The present invention provides polypeptides comprising an immunogenic epitope of aM. vaccaeprotein, polynucleotides encoding such polypeptides, and fusion proteins comprising at least one such polypeptide, together with genetic constructs comprising at least one inventive polynucleotide. Compositions comprising such polypeptides, polynucleotides, fusion proteins and/or genetic constructs may be employed in the treatment of infectious diseases and immune disorders.
REFERENCES:
patent: 6410720 (2002-06-01), Tan et al.
patent: 6436898 (2002-08-01), Delcayre
patent: 2004/0072224 (2004-04-01), Delcayre
Bowie et al. Science Mar. 1990; 247:1306-10.
Rudinger. Peptide Hormones 1976; Jun.:pp. 1-7.
Strugnell et al. Immunl Cell Biol 1997;75:364-69.
Encyclopedia Britannica online.
JFT Griffin, Clinical Infectious Diseases, “Veterinary Tuberculosis Vaccine Development,” Jun. 2000, 30(suppl) ;S223-8.
MJ McCluskie et al., Molecular Medicine , “Route and Method od Delivery of DNA VaccineInfluence Immune Responses in Mice and Non-Human Primates,” May 1999, vol. 5, pp. 287-300.
PEM Fine, Genetics and tuberculosis, “Vaccines, genes and trials,” 1998, 217, pp. 57-72.
Swiss-Prot Accession No. P91408; Geisel C. et al., submitted Dec. 15, 1998.
PIR Accession No. T46707; Ilg, T. et al., submitted Feb. 18, 2000.
PIR Accession No. T28682; Parkhill, J. et al., submitted Oct. 15, 1999.
TREMBL Accession No. Q9S9B2; Raghavan, V. et al., submitted May 1, 2000.
Swiss-Prot Accession No. P06530; Kiss, A. et al., submitted Jan. 1, 1988.
Swiss-Prot Accession No. Q06965; Neidle, E.L. et al., submitted Oct. 1, 1996.
TREMBL Accession No. E968234; LeGoux, R. et al., submitted Nov. 1, 1998.
TREMBL Accession No. E1263321; Van, L.F. et al., submitted Nov. 1, 1998.
GenPept Accession No. CAB45489; James, K.D. et al., submitted Jun. 18, 1999.
GenPept Accession No. CAB07541; Dziadek, J. et al., submitted Mar. 19, 1997.
GenPept Accession No. BAA97474; Nakamura, Y., submitted Apr. 2, 1999.
Swiss-Prot Accession No. P41014; Ishizuka, M., submitted Aug. 1994.
GenPept Accession No. AAF10382; White, O. et al., submitted Nov. 8, 1999.
GenPept Accession No. AAD34368; Janoir, C., et al., submitted Feb. 22, 1999.
GenPept Accession No. AAC70256; Kuzio, J. et al., submitted Aug. 3, 1998.
GenPept Accession No. AAA72555; Tokunaga, T. et al., submitted 1985.
GenPept Accession No. AAB38132; Shago, M. et al., submitted Feb. 29, 1996.
GenPept Accession No. AAC32046; Zhu, W.M. et al., submitted Nov. 11, 1997.
Genesis Research & Development Corporation LTD
Marvich Maria
Nguyen Dave Trong
Sleath Janet
Speckman Law Group PLLC
LandOfFree
Compounds for treatment of infectious and immune system... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for treatment of infectious and immune system..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for treatment of infectious and immune system... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3629817